[A case of metastatic colorectal cancer with hyperammonemic encephalopathy induced by 5-FU in a patient continuously treated with XELOX therapy]

Gan To Kagaku Ryoho. 2013 Dec;40(13):2581-4.
[Article in Japanese]

Abstract

We report a rare case of a patient with metastatic colorectal cancer who experienced hyperammonemic encephalopathy induced by 5 -fluorouracil(5-FU)and was continuously treated with capecitabine plus oxaliplatin(XELOX)therapy. A 60 years man with anorexia and weight loss was diagnosed with Stage IV rectal cancer, and chemotherapy with XELOX was initiated. When the second course of XELOX therapy was administered, the patient found it difficult to take oral capecitabine. Subsequently, modified FOLFOX6 was administered. Complications such as nausea and vomiting were observed on day 2, with confusion and cognitive disturbances on day 3 . Laboratory examination revealed hyperammonemia, and therefore, branched-chain amino acid solutions were administered as treatment. The patient's symptoms disappeared entirely on day 4. He is currently receiving XELOX therapy.

Publication types

  • Case Reports

MeSH terms

  • Amino Acids, Branched-Chain / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brain Diseases, Metabolic / drug therapy
  • Brain Diseases, Metabolic / etiology*
  • Capecitabine
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects*
  • Fluorouracil / analogs & derivatives
  • Fluorouracil / therapeutic use
  • Humans
  • Hyperammonemia / chemically induced
  • Hyperammonemia / drug therapy*
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Male
  • Oxaloacetates
  • Rectal Neoplasms / drug therapy*
  • Rectal Neoplasms / pathology

Substances

  • Amino Acids, Branched-Chain
  • Oxaloacetates
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil

Supplementary concepts

  • XELOX